MMedXYNews
Ask AIHomeVideos
MedXY AI/MedXY News/Tag: amycretin

amycretin

Latest news

Tag

Clinical Updates

Amycretin: A Promising First-in-Class Dual GLP-1 and Amylin Receptor Agonist for Overweight and Obesity

Amycretin, a novel dual GLP-1 and amylin receptor agonist, demonstrated safety, tolerability, and dose-proportional pharmacokinetics in adults with overweight or obesity, supporting further trials on its weight loss efficacy.

Sep 17, 2025
Clinical Updates

Amycretin: A Novel Unimolecular GLP-1 and Amylin Receptor Agonist for Obesity – Early-Phase Clinical Insights and Broader GLP-1 Drug Development Perspective

Amycretin, a new unimolecular GLP-1 and amylin agonist, demonstrated significant weight loss and acceptable tolerability in a phase 1b/2a study, underscoring its potential as an anti-obesity therapy.

Aug 2, 2025Sign in to read

Most read

  1. 01Intimate Health

    Five Benefits for Women Continuing Sexual Activity After Menopause

  2. 02Intimate Health

    Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It

  3. 03Nursing & care

    How often should a couple have sex?

  4. 04Cardiology

    Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval

  5. 05General Surgery

    Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models

Go deeper with MedXY AI

Explore the evidence behind the news.

Ask AI
MedXY briefing

Stay informed

Medical news and research updates, delivered to your inbox.

© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story